Enhanced Sensitivity of PTEN-deficient Tumors to Inhibition of FRAP/mTOR

Proceedings of the National Academy of Sciences of the United States of America - United States
doi 10.1073/pnas.171076798
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Proceedings of the National Academy of Sciences

Related search

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1)

Science-Business eXchange
2010English

Susceptibility of Epithelium to PTEN-Deficient Tumorigenesis

2012English

Enhanced Sensitivity of Laforin- And Malin-Deficient Mice to the Convulsant Agent Pentylenetetrazole

Frontiers in Neuroscience
Neuroscience
2014English

Is There a Causal Link Between PTEN Deficient Tumors and Immunosuppressive Tumor Microenvironment?

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

Extrarenal Perivascular Epithelioid Cell Tumors (PEComas) Respond to mTOR Inhibition: Clinical and Molecular Correlates

International Journal of Cancer
Cancer ResearchOncology
2012English

Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity Through Attenuated DNA Repair

Cancer Cell
Cancer ResearchOncologyCell Biology
2019English

TAZ Inhibition Restores Sensitivity of Cisplatin via AKT/mTOR Signaling in Lung Adenocarcinoma

Oncology Reports
MedicineCancer ResearchOncology
2017English

PI3K/PTEN/Akt/mTOR Pathway Aberrations and Co-Incidence of Hormone Receptors and HER2 in 19,784 Diverse Solid Tumors.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2015English

Mammalian Target of Rapamycin (mTOR; FRAP; RAFT1); Transforming Growth Factor-Β1 (TGFB1; TGFβ1)

Science-Business eXchange
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy